South African billionaire Johann Rupert’s net worth drops below $17 billion
Johann Rupert’s net worth falls $800 million to $16.3 billion amid Richemont’s 6.5% share decline despite strong global jewelry sales.
Skip to content
Johann Rupert’s net worth falls $800 million to $16.3 billion amid Richemont’s 6.5% share decline despite strong global jewelry sales.
Johann Rupert will receive a $20.7 million dividend from Reinet Investments after the Luxembourg-based firm reported strong asset growth in its latest fiscal year.
Discovery Limited's stock gains lift Barry Swartzberg’s fortune, reinforcing confidence in South Africa’s financial services sector.
This increase highlights the family's position as one of South Africa’s wealthiest.
Jannie Mouton gains $28 million in 24 days as Capitec shares rally, driven by digital-first banking and rising investor confidence on the JSE.
The restructured entity now controls a portfolio worth over $65 billion, effectively doubling its asset base in Australia.
FMB Capital’s stock dips 30%, slashing Hitesh Anadkat’s stake by $274 million. Yet, investors stay confident in the regional banking powerhouse.
Aspen’s investment comes amid a broader push to localize manufacturing, enhance drug supply chains, and develop regional talent.
Barloworld prolongs Russia probe through Sept. 2025 amid sanctions pressure, falling revenue, and possible delisting via Zahid Group-backed buyout.
The miners were stranded Thursday after a skip door on a rock winder opened unexpectedly at Level 39, disrupting access to lower levels.
Pick n Pay, partly owned by the Ackerman family, posted $6.8 billion revenue in 2025 as Boxer growth and recapitalization drove a sharp cut in losses.
The payment resolves all pending litigation between the two state-backed firms, according to a Sens announcement issued after the market closed on Friday.
South Africa's media landscape shifts as Caxton & CTP Publishers stock dips, impacting CEO Terrence Moolman’s fortune.
According to Forbes estimates, his net worth rose from $3 billion in mid-March to $3.2 billion by late May.
This mirrors wider investor caution amid challenges facing the global pharmaceutical sector and instability in emerging markets.
The continued slide in the company’s share price on the Malawi Stock Exchange has dragged down his holdings significantly.